SubHero Banner

Keytruda® (pembrolizumab) – Expanded indication

June 19, 2018 - The FDA approved Merck’s Keytruda (pembrolizumab), for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 [Combined Positive Score (CPS) ≥ 10], or in patients who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status.

Download PDF